NEW YORK (GenomeWeb News) — A branch of the US Department of Health and Human Services responsible for developing responses to bioweapons is seeking applicants to develop bioassay technologies that could be used in the event of a nuclear detonation or of a radiological device, or 'dirty bomb,' to assess the radiation doses to which people have been exposed.
The Biomedical Advanced Research and Development Authority (BARDA) program will fund advanced development of biomarkers, bioassays, biological dosage measurement tools that could be used to create a rapid point-of-care diagnostic tool for post-nuclear or radiological events.
Those seeking to apply for the support should request funds to advance "a promising diagnostic product" and should propose "a well-defined product development path that must include completion and validation, and potentially approval/clearance, of a prototype instrument or bioassay prior to or within five years of the contract period."
Once a radiation-responsive biomarker is qualified, the development of a diagnostic test and the validation of a biomarker assay will fall under the Office of In Vitro Diagnostic Device and Safety for clearance or approval.
More information about the BARDA funding opportunity can be found here.